Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis (GCA). Study of efficacy and safety of secukinumab 300 mg and 150 mg in patients with giant cell arteritis ...
A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to investigate the efficacy and safety of secukinumab 300 mg and 150 mg administered subcutaneously versus placebo, in combination with aglucocorticoid taper regimen, in patients with giant cell arteritis (GCA) A randomized, parallel-group, double-blind, placebo-controlled, multicenter Phase III trial to inves ...
United States;Portugal;Estonia;Spain;Russian Federation;Switzerland;Italy;France;Australia;Denmark;South Africa;Netherlands;Czechia;Finland;Guatemala;Turkey;United Kingdom;Hungary;Canada;Argentina;Poland;Brazil;Belgium;Bulgaria;Germany;Norway;New Zealand;Sweden United States;Portugal;Estonia;Spain;Russian Federation;Switzerland;Italy;France;Australia;Denmark;S ...